Related Experiment Videos
Augmenting tumor sensitivity to topotecan by transient hypoxia
Eva L Lund1, Lasse T Hansen, Paul E G Kristjansen
1Laboratory of Experimental Oncology, Department of Molecular Pathology, University of Copenhagen, Denmark. eva@pai.ku.dk
Cancer Chemotherapy and Pharmacology
|May 17, 2005
Summary
Transient hypoxia enhances topotecan efficacy against tumors by increasing cancer cell sensitivity and reducing tumor angiogenesis. This combination therapy shows greater tumor growth suppression than either treatment alone.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Topotecan is a chemotherapy drug used to treat various cancers.
- Hypoxia, or low oxygen levels, is common in solid tumors and can affect treatment response.
- The interaction between topotecan and hypoxia requires further investigation.
Purpose of the Study:
- To investigate how transient hypoxia modulates the anti-tumor effects of topotecan.
- To determine if hypoxia enhances topotecan's efficacy in different cancer types.
- To explore the underlying mechanisms of hypoxia-mediated topotecan potentiation.
Main Methods:
- In vivo studies using tumor-bearing mice (Lewis lung carcinoma, U87 glioblastoma, DMS273 small cell lung cancer) treated with topotecan and exposed to hypoxia or normoxia.
- In vitro clonogenic survival assays to assess cancer cell sensitivity to topotecan under hypoxic conditions.
- Analysis of HIF-1alpha, Glucose transporter-1, and VEGF expression and secretion in response to topotecan and hypoxia.
Main Results:
- Topotecan combined with transient hypoxia significantly suppressed tumor growth more than normoxic topotecan or hypoxia alone.
- Hypoxia increased the sensitivity of Lewis lung carcinoma cells to topotecan.
- Topotecan dose-dependently downregulated HIF-1alpha and inhibited hypoxia-induced VEGF secretion, suggesting an anti-angiogenic effect.
- The enhanced effect of topotecan under hypoxia was specific, as cisplatin efficacy was unaffected by hypoxia.
Conclusions:
- Transient hypoxia potentiates the anti-tumor activity of topotecan.
- This potentiation may involve direct effects on cancer cell survival and an anti-angiogenic mechanism mediated by HIF-1 inhibition.
- The findings suggest a potential therapeutic strategy combining topotecan with controlled hypoxic exposure for improved cancer treatment.